KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBT (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EBT for 13 consecutive years, with -$104.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 40.52% to -$104.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$344.9 million, a 41.69% decrease, with the full-year FY2025 number at -$344.9 million, down 41.69% from a year prior.
  • EBT was -$104.7 million for Q4 2025 at Xenon Pharmaceuticals, down from -$90.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$15.6 million in Q3 2021 to a low of -$104.7 million in Q4 2025.
  • A 5-year average of -$48.3 million and a median of -$44.5 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 10332.71% in 2021, then dropped 1.37% in 2023.
  • Xenon Pharmaceuticals' EBT stood at -$25.1 million in 2021, then tumbled by 44.56% to -$36.3 million in 2022, then decreased by 1.37% to -$36.8 million in 2023, then tumbled by 102.76% to -$74.5 million in 2024, then tumbled by 40.52% to -$104.7 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's EBT are -$104.7 million (Q4 2025), -$90.2 million (Q3 2025), and -$85.3 million (Q2 2025).